Top-News

Mateon Therapeutics News

Keine aktuellen Kursdaten verfügbar
WKN: A2AME1
ISIN: US57667K1097
Typ: Aktie

Mateon Therapeutics News

08.12.16 - PR Newswire
OTC Markets Group Welcomes Mateon Therapeutics to OTCQX
OTC Markets Group Welcomes Mateon Therapeutics to OTCQX PR Newswire
31.03.10 - Aktiencheck
Oxigene "buy" - Roth Capital
Rating-​Update: Newport Beach (aktiencheck.de AG) - Die Analysten von Roth Capital stufen die Aktie von Oxigene in einer Ersteinschätzung mit "buy" ein. Das Kursziel sehe man bei ...
15.07.08 - Hugin
OXiGENE Promotes Senior Executive
WALTHAM, Mass., July 15, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-​stage, biopharmaceutical company developing novel ...
28.05.08 - Hugin
OXiGENE Announces Clinical Trials Data to be Presented At the 2008Annual Meeting of the American Society of Clinical Oncology
WALTHAM, Mass., May 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-​stage, biopharmaceutical company developing novel ...
05.05.08 - Hugin
OXiGENE Reports First Quarter 2008 Results
WALTHAM, Mass., May 5, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-​stage, biopharmaceutical company developing novel therapeutics to ...
30.04.08 - Hugin
OXiGENE Announces Preclinical Data Demonstrating that the ActiveMetabolite of ZYBRESTAT Improves Glucose Metabolism through SimilarMechanism as a Sirtuin Agonist
Combretastatin-A4 and Its Analog, Resveratrol, Appear to Activate Same Pathways   WALTHAM, Mass. -- April 30, 2008--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) a clinical-...
28.04.08 - Hugin
OXiGENE Announces First Quarter 2008 Earnings Conference Call andWebcast
WALTHAM, Mass., April 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-​stage, biopharmaceutical company developing novel therapeutics ...
26.03.08 - Hugin
OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combinationwith Bevacizumab and Chemotherapy
WALTHAM, Mass.-- March 26, 2008 --OXiGENE, Inc., a clinical-​stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that ...
11.03.08 - Hugin
OXiGENE to Present at Cowen Healthcare Conference on March 18, 2008
WALTHAM, MA --(BUSINESS WIRE)-- March 11, 2008-- OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics ...
28.02.08 - Hugin
OXiGENE Reports Fourth Quarter and Year-End 2007 Results
Company Provides Updates; Milestones; Financial Guidance for 2008 WALTHAM, MA -- February 28, 2008 -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-​stage, ...
21.02.08 - Hugin
OXiGENE Announces Fourth Quarter and Fiscal 2007 Earnings ConferenceCall and Webcast
WALTHAM, MA -- February 21, 2008 -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-​stage, biopharmaceutical company developing novel therapeutics to treat cancer and ...
20.02.08 - Hugin
OXiGENE Inc. Secures $40 Million Committed Equity Financing Facility
WALTHAM, Mass.--February 20, 2008--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical-​stage, biopharmaceutical company developing novel therapeutics to treat cancer ...
05.02.08 - Hugin
OXiGENE to Present at BIO CEO and Investor Conference on February 12,2008
WALTHAM, Mass.--(BUSINESS WIRE) - February 5, 2008--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical stage, biopharmaceutical company developing novel ...
31.12.07 - Hugin
OXiGENE Reports Positive Preclinical Ocular Penetration Data withTopical Formulation of ZYBRESTAT(TM) for Ophthalmology
Key Feasibility Hurdle Overcome in Topical Ophthalmology Program WALTHAM, MA-​December 31, 2007-OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-​stage, ...
31.12.07 - Hugin
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) inPlatinum-Resistant Ovarian Cancer
Meets Pre-​specified Primary Efficacy Endpoint in Stage 1 of Simon Two-Stage Study WALTHAM, MA-- December 31, 2007 -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-...
11.12.07 - Hugin
OXiGENE TO REPORT ON ZYBRESTAT(TM) PIVOTAL TRIAL PROGRESS INPRESENTATION TO INVESTORS IN SWEDEN
WALTHAM, MA - December 11, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-​stage, biopharmaceutical company developing novel therapeutics to treat cancer and ...
28.11.07 - Hugin
OXiGENE'S ZYBRESTAT(TM) Reported to have Anti-Leukemic Effects inPreclinical Studies Published in Blood
Results Suggest Broader Clinical Potential for Novel Anti-​Cancer Drug Candidate WALTHAM, MA - November 28, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-...
26.11.07 - Hugin
OXiGENE To Present at LAZARD Healthcare Conference on November 28
WALTHAM, Mass.-- November 26, 2007 -- OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical-​stage, biopharmaceutical company developing novel therapeutics to treat ...
01.11.07 - Hugin
OXiGENE Reports Third Quarter 2007 Results, Clinical and CorporateHighlights
Waltham, MA - November 1, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-​stage biopharmaceutical company developing novel therapeutics to treat cancer and ...
24.10.07 - Hugin
OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-ActionData Published in Peer-Review Journal
WALTHAM, MA - October 24, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-​stage, biopharmaceutical company developing novel therapeutics to treat cancer and ...

Newssuche

Videos

newspaper
24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »